Ironwood Pharmaceuticals Inc - Ordinary Shares - Class A
IRWD
Get informed when a big investor buys or sells
+ FollowMarket Cap$610.71M
Close$
$12.07
225.5% upside
Current Fair Value
225.5% upsideUndervalued by 225.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $610.71 Million |
|---|---|
| Enterprise Value | $602.60 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0.15 |
| Beta | 0.21 |
| Outstanding Shares | 163,451,000 |
Return
| Return on Equity | -2243.88% |
|---|---|
| Return on Assets | 55.92% |
| Return on Invested Capital | 102.67% |
Valuation & Multiples
| P/E Ratio | 5.83 |
|---|---|
| PEG | -1.72 |
| Price to Sales | 1.86 |
| Price to Book Ratio | -3.71 |
| Enterprise Value to Revenue | 1.67 |
| Enterprise Value to EBIT | 2.96 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.35 |
| Debt to Equity | -19.61 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 7, 2026
EPS Estimate
$0.07
Average shareholder expectationRevenue Estimate
$92.11 M
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$0.32
Average shareholder expectationRevenue Estimate
$116.97 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 3.48% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.88%▼ 98.66% |
|---|---|
| Total Invested | $6.02M▼ 98.94% |
| Investors Holding | 20▼ 214.00% |
ESG Score
No data
About Ironwood Pharmaceuticals Inc
CEO: Mark Mallon